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Abstract
We evaluated the plasma homocysteine (tHcy) and nitric oxide metabolites (nitrite plus ni-
trate; NOx) data of consecutive patients undergoing diagnostic coronary angiography (n=79) with
respect to the presence and severity of coronary artery disease (CAD), the presence of acute coro-
nary syndromes (ACS), and the risk status of patients. Hyperhomocysteinemia (>15 micromol/L)
was detected in 11% of the controls (n=19) and 37% of CAD patients (n=60) (p=0.03). Plasma
tHcy in CAD patients was not significantly different from controls, but those with 3-vessel disease
had a significantly higher tHcy concentrations than did controls (p=0.049). The patients with 3-
vessel disease and ACS had the highest concentrations of tHcy (16.9 +- 4.4 micromol/L), and the
difference from the ACS patients with 1- and 2-vessel involvement was significant (p=0.03). In
patients with 1-vessel involvement, tHcy was correlated with NOx (r=0.62, p=0.005); in patients
with 2- and 3-vessel disease this correlation could not be observed. The high-risk patients (n=51)
had a higher mean number of vessel involvement and tHcy (p<0.001, p<0.05, respectively) but
lower NOx (p<0.05) when compared to the low-risk patients (n=28). It appears that in the early
stages of atherosclerosis hyperhomocysteinemia causes an increase in NOx production, but with
progression of the disease this compensatory increase disappears.
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omocysteine is an amino acid with a sulphydryl 
group,  formed by demethylation of methionine. 
It is converted to cystathionine by B6-dependent cys-
tathionine ｹ-synthase and remethylated to methionine 
by B12-dependent 5-methyl tetrahydrofolate-homocys-
teine methyltransferase.  Major causes of hyperhomo-
cysteinemia are age,  renal failure,  excessive coﬀ ee 
consumption,  drugs including methotrexate,  phenyt-
oin,  and theophylline,  dietary deﬁ ciencies of vitamin 
cofactors (folic acid,  vitamin B6,  and vitamin B12), 
or abnormalities in the enzymes required for homo-
cysteine metabolism (cystathionine ｹ-synthase, 
5,10-methylenetetrahydrofolate reductase) [1ﾝ3].
　　In the last decade,  moderate elevation of homo-
cysteine has been shown to be associated with coro-
nary,  cerebral,  and peripheral vascular diseases. 
Moreover,  hyperhomocysteinemia has been accepted 
as an independent risk factor for cardiovascular dis-
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ease [4ﾝ8].  Although there is considerable epidemio-
logic and clinical evidence for these associations, 
angiographic studies have shown contradictory 
results regarding the relationship between homocys-
teine and the severity of atherosclerosis [9ﾝ11].  In 
addition,  the exact mechanism through which homo-
cysteine exerts its eﬀ ects on the arteries is still not 
clear.  Although previous reports have shown an 
association of hyperhomocysteinemia with abnormali-
ties in nitric oxide synthesis and impaired endothe-
lium-dependent vasodilatation,  studies investigating 
both homocysteine and nitric oxide in angiographi-
cally evaluated patients are lacking [12,  13].  Thus 
in this study,  in patients undergoing diagnostic coro-
nary angiography,  we determined homocysteine and 
nitric oxide metabolites (nitrite plus nitrate ; NOx) 
[14] in plasma and evaluated the data with respect 
to the presence and severity of coronary artery dis-
ease (CAD),  to the presence of acute coronary syn-
dromes (ACS),  and also to the risk status of patients 
determined by the number of other major coronary 
risk factors present.
Materials and Methods
　　Study groups.　 The study protocol was 
approved by the local Research Ethical Committee, 
and an informed consent was obtained from each 
patient.  The study group consisted of 79 consecutive 
patients (51 men and 28 women,  mean age 56 ± 10 
years) undergoing selective coronary angiography. 
All patients had normal renal and liver function and 
no evidence of malignant disease,  and they also did 
not take vitamin supplements or medications such as 
intravenous nitrates that could interfere with the 
analysis of either homocysteine or NOx.
　　Clinical indications for coronary angiography 
were ACS (myocardial infarction or unstable angina 
pectoris) for 40 patients (51ｵ) and diagnosis of CAD 
for 39 patients (49ｵ).
　　Coronary angiography.　 Diagnostic left heart 
catheterization and coronary angiography were per-
formed by a percutaneous femoral approach with the 
Judkins procedure.  Three experienced cardiologists 
who were unaware of the laboratory data on homo-
cysteine and nitric oxide reviewed all angiograms 
simultaneously.  Signiﬁ cant CAD was deﬁ ned as a 
stenosis of more than 50ｵ of the vessel diameter. 
Severity of CAD was assessed according to the num-
ber of vessels with signiﬁ cant stenosis.  Patients 
were divided into 2 groups : 1) Control group,  CAD 
(－),  consisting of patients with normal coronary 
arteries (n ＝ 19),  2) Coronary artery disease group, 
CAD (＋),  consisting of patients with signiﬁ cant ste-
nosis in at least one epicardial coronary artery 
(n ＝ 60).  The CAD (＋) patients were further 
grouped according to the number of vessels 
involved : 1-vessel disease (n ＝ 19),  2-vessel disease 
(n ＝ 21),  or 3-vessel disease (n ＝ 20).  These 1-vessel, 
2-vessel,  and 3-vessel patients were further grouped 
according to the presence or absence of acute coro-
nary syndrome,  as ACS (＋) and ACS (－).
　　The study group was also grouped as low-risk and 
high risk,  evaluating male gender,  age (＞ 45 years 
for males and ＞ 55 years for females),  family history 
of coronary artery disease,  diabetes mellitus,  hyper-
tension (＞ 140/90 mmHg),  smoking status,  and 
hypercholesterolemia (total cholesterol higher than 
200 mg/dl) as major risk factors.  Patients with 
fewer than 3 risk factors were deﬁ ned as belonging 
to the low-risk group,  and patients with 3 and more 
risk factors or with diabetes mellitus were deﬁ ned as 
belonging to the high-risk group.
　　Biochemical Measurements.　 Blood samples 
were withdrawn from the antecubital veins after an 
overnight fast,  and the plasma samples were stored 
at － 70 °C until analysis.
　　Plasma total homocysteine (tHcy) was measured 
by using an EIA kit (BioRad,  Norway).  Nitric oxide 
was determined by spectrophotometric measurement 
of nitrite plus nitrate (NOx),  which are stable oxida-
tion products of nitric oxide (Roche-Boehringer 
Mannheim,  Germany) [15].
　　Total cholesterol and LDL cholesterol were 
determined by the CHOD-PAP enzymatic method 
(Diasys Diagnostic Systems GmbH & Co.  KG., 
Germany) adapted to an Olympus AU 800 autoana-
lyzer.  Serum triglyceride concentration was mea-
sured by the enzymatic GPO-PAP method (Diasys 
Diagnostic Systems GmbH & Co.).  HDL cholesterol 
was determined after precipitation of apoB-containing 
lipoproteins with phosphotungstic acid and magne-
sium chloride by the Olympus AU 800 autoanalyzer.
　　Statistical Analysis.　 Categorical variables 
are given as counts (percentages) and continuous vari-
ables as the mean ± standard deviation (SD).  For 
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comparisons of controls and ACS (－) and ACS (＋) 
patients or high-risk and low-risk patients,  we used 
an unpaired Student’s t-test (or Mann-Whitney U-test 
when necessary) to examine continuous variables and 
a chi-square test for categorical variables. 
Diﬀ erences between controls,  1-,  2-,  and 3-vessel 
involvements were examined by one-way variance 
analysis.  Correlations of homocysteine and NOx with 
age and serum lipid concentrations were examined 
using Spearman’s rank correlation analysis and with 
angiographic vessel involvement by linear regression 
analysis.  A p value ＜ 0.05 was considered signiﬁ -
cant.
Results
　　Patient characteristics.　 On evaluation of the 
coronary artery disease patients according to the 
severity of atherosclerosis,  19 (32ｵ) had 1-vessel, 
21 (35ｵ) had 2-vessel,  and 20 (33ｵ) had 3-vessel 
disease.  ACS was the indication for coronary angi-
ography in 51ｵ of the patients (n ＝ 40).
　　Major risk factors for CAD (age,  male gender, 
hypertension,  family history,  diabetes mellitus, 
hypercholesterolemia,  and smoking) were assessed in 
the patients,  who were then grouped according to 
their total risk status.  There were 51 high-risk 
patients and 28 low-risk patients.
　　Major risk factors for CAD are compared 
between controls and patients in Table 1.  Signiﬁ cant 
diﬀ erences were noted for age,  male gender,  and 
total number of risk factors.  Total cholesterol,  LDL 
cholesterol,  HDL cholesterol,  and triglyceride con-
centrations of the study groups are shown in Table 2.
　　Plasma Homocysteine and NOx.　 Hyperhom
ocysteinemia,  deﬁ ned as a plasma level of higher 
than 15 µmol/L,  was present in 11ｵ of the controls 
and 37ｵ of the coronary artery disease patients 
(p ＝ 0.03).  Half of the patients with 3-vessel disease 
had hyperhomocsyteinemia.
　　The tHcy and NOx concentrations of plasma were 
not observed to be signiﬁ cantly diﬀ erent between 
patients with and without signiﬁ cant coronary lesions 
(Table 3).  However,  patients with 3-vessel disease 
had signiﬁ cantly higher homocysteine concentrations 
when compared to the patients with normal coronary 
arteries (p ＝ 0.049).
　　Homocysteine concentration was higher in patients 
with an acute coronary syndrome compared to 
patients without an acute event,  but the diﬀ erence 
did not achieve statistical signiﬁ cance (Table 4). 
However,  the patients with 3-vessel disease and ACS 
had the highest concentrations of plasma homocyste-
ine (16.9 ± 4.4 µmol/L),  and the diﬀ erence from the 
acute coronary syndrome patients with 1- and 2-ves-
sel involvement was statistically signiﬁ cant (p ＝ 0.03). 
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Table 1　　Major risk factors in the study groups
 CAD (－) CAD (＋)
 Control 1-vessel 2-vessel 3-vessel  Disease Disease Disease Total
 (n＝19) (n＝19) (n＝21) (n＝20) (n＝60)
Major risk factors
　Age 52 ± 9  59 ± 10 55 ± 11 61 ± 10 58 ± 10a＊
　Male gender (%) 37 79 67 75  73a＊＊
　Hypertension (%) 53 32 48 50 43　
　Diabetes mellitus (%) 11 11 14   35b＊ 20　
　Family history (%) 18  6 39 37 28　
　Hypercholesterolemia 41 38 47 60 48　
　Smoking (%) 26 47 52 35 45　
　Number of risk factors 2.4 ± 1.6 3.0 ± 1.1 3.5 ± 1.3 4.0 ± 1.3b＊ 3.5 ± 1.3a＊＊
Values are means ± SD.
CAD (－) : patients with normal coronary arteries.
CAD (＋) : patients with signiﬁ cant coronary artery stenosis.
a : vs CAD (－),  b : vs 1- and 2-vessel disease.
＊p ＜ 0.05,  ＊＊p ＜ 0.01
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As evident from Table 4,  no signiﬁ cant diﬀ erences 
were observed for nitric oxide when coronary artery 
disease patients were evaluated with respect to the 
presence of ACS.
　　The patients with higher risk had higher homocys-
teine concentrations compared to the low-risk group 
patients (p ＝ 0.049) (Table 5).  Patients with higher 
risk had signiﬁ cantly lower NOx concentrations com-
pared to low-risk group patients (p ＝ 0.04).  Mean 
numbers of vessel involvement were signiﬁ cantly 
higher in the high-risk group than in the low-risk 
group (p ＜ 0.001).
　　The tHcy and NOx levels showed a moderate posi-
tive correlation in patients with 1-vessel involvement 
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Table 2　　Cholesterol and triglyceride concentrations of plasma in the study groups
 CAD (－) CAD (＋)
 Control 1-vessel 2-vessel 3-vessel  Disease Disease Disease Total
 (n＝19) (n＝19) (n＝21) (n＝20) (n＝60)
Parameters
　Total chol.  (mg/dl) 197 ± 45 189 ± 35 211 ± 48 209 ± 43 204 ± 131
　HDL-chol.  (mg/dl) 43 ± 12 42 ± 14 48 ± 11 41 ± 12 44 ± 13
　LDL-chol.  (mg/dl) 127 ± 38 114 ± 27 140 ± 39 137 ± 33 131 ± 35
　Triglycerides (mg/dl) 161 ± 102 152 ± 70 137 ± 65 163 ± 58 150 ± 64
Values are means ± SD.
CAD (－),  patients with normal coronary arteries ; CAD (＋),  patients with signiﬁ cant coronary artery stenosis.
Table 3　　Homocysteine and NOx concentrations of plasma in the study groups
 CAD (－) CAD (＋)
 Control 1-vessel 2-vessel 3-vessel  Disease Disease Disease Total
 (n＝19) (n＝19) (n＝21) (n＝20) (n＝60)
Homocysteine (µmol/L) 11.5 ± 3.9 12.7 ± 5.5 12.7 ± 3.3 15.4 ± 7.2＊ 13.6 ± 5.6
NOx (µmol/L) 40.2 ± 18.9 45.8 ± 18.3 49.3 ± 19.3 49.5 ± 23.9 48.3 ± 20.4
Values are means ± SD.
CAD (－),  patients with normal coronary arteries ; CAD (＋),  patients with signiﬁ cant coronary stenosis ; NOx,  Nitrite plus nitrate.
＊p ＜ 0.05 vs CAD (－).
Table 4　　Homocysteine and NOx concentrations of plasma in the coronary artery disease patients with and without acute coronary syn-
drome
1-vessel disease 2-vessel disease 3-vessel disease Total
ACS (－) ACS (＋) ACS (－) ACS (＋) ACS (－) ACS (＋) ACS (－) ACS (＋)
(n ＝ 5) (n ＝ 14) (n ＝ 6) (n ＝ 15) (n ＝ 9) (n ＝ 11) (n ＝ 20) (n ＝ 40)
Homocysteine (µmol/L) 10.4 ± 5.6 13.1 ± 5.9 11.4 ± 2.7 12.7 ± 3.4 14.6 ± 9.5 16.9 ± 4.4＊ 12.9 ± 7.37 14.1 ± 4.9
NOx (µmol/L) 40.1 ± 8.7 46.1 ± 21.6 54.1 ± 15.9 45.3 ± 17.4 51.9 ± 24.2 44.3 ± 23.6 50.5 ± 19.8 45.3 ± 20.2
Values are means ± SD.
ACS (－),  absence of acute coronary syndrome ; ACS (＋),  presence of acute coronary syndrome ; NOx,  Nitrite plus nitrate.
＊p ＜ 0.05 vs 1-vessel and 2-vessel disease patients with acute coronary syndrome.
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(r ＝ 0.62,  p ＝ 0.005) (Fig.  1).  This positive correla-
tion disappeared in patients with 2-vessel disease 
and,  though nonsigniﬁ cant,  the correlation became 
negative in patients with 3-vessel involvement 
(r ＝ －0.28,  p ＝ 0.23).
　　On further evaluation of tHcy and NOx correla-
tion with respect to ACS (－) and ACS (＋) classiﬁ -
cation in 1-vessel,  2-vessel,  and 3-vessel patients,  we 
observed a positive correlation only in the ACS (＋) 
1-vessel disease patients (r ＝ 0.566,  p ＝ 0.044) and 
not in the ACS (＋) patients with 2- or 3-vessel dis-
ease.
　　Plasma homocysteine was signiﬁ cantly correlated 
only with age in the whole study group (r＝
0.30 ; p ＝ 0.008).  Plasma NOx was not correlated 
with any of the risk factors.  Total number of risk 
factors was the most signiﬁ cantly related factor to 
the number of vessels involved (r ＝ 0.29 ; p ＝ 0.002) 
when adjusted for age,  LDL-cholesterol,  HDL-
cholesterol,  level of homocysteine,  and NOx.
Discussion
　　Hyperhomocysteinemia has been accepted as an 
independent risk factor for cardiovascular disease [4
ﾝ8].  Even mildly elevated plasma homocysteine con-
centration has been associated with increased risk of 
cardiovascular disease [11,  16].  Phenotypically, 
hyperhomocysteinemia-associated vascular disease is 
characterized by vascular lesions,  endothelial dys-
function,  smooth muscle cell proliferation,  and plate-
let hyperreactivity [17,  18]. These phenotypic 
changes have largely been replicated in experimental 
models of hyperhomocysteinemia [19,  20].  Previous 
reports have shown an association of hyperhomocys-
teinemia with abnormalities in nitric oxide synthesis 
and impaired endothelium-dependent vasodilatation 
[14,  18,  21,  22].  However,  to the best of our 
knowledge,  this is the ﬁ rst study in which homocys-
teine,  nitric oxide,  and coronary atherosclerosis 
have been studied in an angiographic study.
　　In the present study,  we observed no statistically 
signiﬁ cant diﬀ erence in plasma total homocysteine 
levels between controls and patients with coronary 
artery disease.  However,  the frequency of hyperho-
mocysteinemia was signiﬁ cantly higher in coronary 
artery disease patients,  with half of the 3-vessel dis-
ease patients having hyperhomocsyteinemia.  Among 
3-vessel disease patients,  those with ACS had the 
highest concentrations of plasma homocysteine. 
Patients with a recent history of ACS have also been 
previously reported to have higher homocysteine lev-
els [22].  Thus our ﬁ ndings reﬂ ect that higher levels 
of plasma homocysteine are signiﬁ cantly linked to the 
extent of coronary atherosclerosis.
　　Importantly,  we observed a moderate signiﬁ cant 
positive correlation between homocysteine and NOx 
in 1-vessel disease patients.  Since NOx concentra-
tion is considered to be a measure of NO production 
[15],  this correlation suggests that in the early 
stages of atherosclerosis NO production increases to 
serve as a compensatory mechanism for the restric-
tion of the endothelial damage,  atherosclerotic 
plaque formation,  and thrombotic events.  NO also 
exhibits an antioxidant action with respect to lipid 
39Homocysteine and NO in Coronary angiographyFebruary 2006
Table 5　　Homocysteine,  nitric oxide,  and number of vessels 
involved of plasma in low- and high-risk coronary angiography 
patients
 Coronary Angiography Patients
 Low risk High risk
 (n ＝ 28) (n ＝ 51)
Total number of risk factors 1.75 ± 0.52 4.04 ± 1.07＊＊＊
Number of vessels involved 0.89 ± 0.96 1.9 ± 1.1＊＊＊
Homocysteine (µmol/L) 11.6 ± 5.1 13.9 ± 5.3＊
NOx (µmol/L) 53.7 ± 23.1 46.3 ± 19.2＊
Values are means ± SD.
NOx : Nitrite plus nitrate.
＊p ＜ 0.05,  ＊＊＊p ＜ 0.001.
r =0.62
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Fig. 1　　Correlation between plasma homocysteine and NOx 
(nitrite plus nitrate) in patients with 1-vessel disease.
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peroxidation [18].  The disappearance of this posi-
tive correlation in the 2-vessel disease patients and, 
though non signiﬁ cant,  the tendency to a negative 
correlation in the 3-vessel disease patients suggest 
the failure in this compensation mechanism with the 
progression of the disease.  Consistent with these 
earlier ﬁ ndings,  we observed lower NO production 
in patients with high risk.  These high-risk patients 
had both signiﬁ cantly higher homocysteine concentra-
tion and a higher mean number of vessel involvement. 
We observed that only age,  and not the other risk 
factors,  was signiﬁ cantly correlated with homocyste-
ine,  which in turn is in accordance with the fact that 
hyperhomocysteinemia has an independent eﬀ ect on 
coronary atherosclerosis [22,  23].
　　Angiographic studies have shown contradictory 
results with regard to the relationship between homo-
cysteine and the severity of atherosclerosis.  Tsai et 
al. showed a positive correlation between angio-
graphic score and homocysteine in patients without 
ACS [23].  Diﬀ erent from Tsai et al., we used simple 
scoring with number of vessel involvement and ACS. 
We observed that hyperhomocysteinemia is associ-
ated with number of vessel involvement in high-risk 
group patients,  and this was more evident in patients 
with ACS.  The mechanism by which homocysteine 
promotes atherothrombosis is not yet clear.
　　Homocysteine has been shown to be associated 
with impairment in both production and bioavailabil-
ity of endothelial-derived NO,  which has a protective 
eﬀ ect as both a potent vasodilatator and a platelet 
inhibitor [14,  18].  Furthermore,  homocysteine 
itself also promotes the formation of thrombin [22]. 
A commonly held view is that oxidative stress may be 
an important contributing factor in the promotion of 
atherothrombosis by homocysteine.  Homocysteine 
autooxidation in hyperhomocysteinemia causes the 
generation of reactive oxygen species (ROS) and 
mediates endothelial damage [24].  Superoxide anion 
radicals interact with nitric oxide,  causing the for-
mation of peroxynitrite and thus the loss in NO bio-
availability [18,  21].
　　Homocysteine also inhibits cellular glutathione 
peroxidase expression in endothelial cells,  an eﬀ ect 
that would induce oxidative stress by itself [14,  21]. 
Superoxide anion radicals and peroxynitrite also 
cause oxidation of sulphydryl groups of endothelial 
nitric oxide synthase (eNOS),  leading to a lower NO 
output [18].  Through a process known as eNOS 
“uncoupling” eNOS can also generate superoxide. 
This process appears to occur under conditions typi-
cally associated with vascular disease and in relative 
deﬁ ciency of tetrahydrobiopterin.  On the other hand, 
homocysteine has been shown to upregulate inducible 
nitric oxide synyhase (iNOS) enzyme activity by 
NF-κB-dependent transcriptional activation in rat 
aortic smooth muscle cells and cause a dose-depen-
dent increase in nitric oxide content of cells [25]. 
This suggests the contribution of homocysteine to the 
inﬂ ammatory response that characterizes early ath-
erosclerosis.
　　It has been suggested that NO production by vas-
cular smooth muscle cells may in part compensate for 
the absence of endothelial NO synthesis and may sup-
press the atherothrombotic risk of a hyperhomocyste-
inemic state [15].  On the other hand,  NO attenuates 
the pathogenicity of homocysteine by reacting with 
its thiol group and the product,  S-NO-homocysteine, 
has potent vasodilatory and antiplatelet eﬀ ects.  The 
progressive imbalance between NO production and 
homocysteine resulting in decreased S-NO formation 
has been suggested to account for the adverse vascu-
lar properties of homocysteine [26].  The positive 
correlation that we observed between homocysteine 
and nitric oxide production in 1-vessel disease 
patients but not in 2- and 3-vessel disease patients 
may be due to the above-mentioned compensatory NO 
production by iNOS or the existence of such a pro-
tective mechanism in the early stages of atheroscle-
rosis.
　　To conclude,  our study investigating a patient 
group who underwent diagnostic coronary angiogra-
phy shows that higher levels of plasma total homocys-
teine aresigniﬁ cantly linked to the extent of coronary 
atherosclerosis.  Despite being investigated in a rela-
tively limited number of patients,  our study shows a 
positive correlation between nitric oxide production 
and homocysteine in-vivo for the ﬁ rst time and 
implies that a failure in nitric oxide compensation 
may be important in the progression of atherosclero-
sis and acute coronary events.
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